Individuals find the right products. Businesses reach the right audience. One platform, free for both.
Since 2023, Ohara Pharmaceutical has backed 2 African startups across 3 disclosed funding rounds totaling $39.6M, most heavily in Health Tech.
Ohara Pharmaceutical Co., Ltd. is a pharmaceutical company based in Shiga, Japan. Its official website describes its work in orphan drugs and affordable generic medicines. The company has also publicly announced investments in African healthcare businesses. Ohara Pharmaceutical’s recorded African investments are in health technology companies in Kenya and Nigeria. The recorded portfolio includes MYDAWA in Kenya and Helium Health in Nigeria. The rounds span a Series B, a venture round with no specified round label, and an “Other” round, so the available information does not establish a single preferred investment stage.
Data updated · Oct 10, 2026
Ohara Pharmaceutical has backed 2 African startups across 3 disclosed funding rounds tracked on Liners, totaling $39.6M since 2023.
Mostly Other: 1 of its 3 tracked rounds are at that stage, followed by Venture (Round not Specified) (1).
Its tracked rounds lean toward Health Tech (3).
Ohara Pharmaceutical most often shares rounds with AAIC Investment (2 shared deals), Creadev (2 shared deals), IFU (1 shared deal).
The recorded portfolio includes MYDAWA in Kenya and Helium Health in Nigeria. The investment records list three rounds across these two companies.
The recorded investment activity spans June 2023 to April 2025. The records list three rounds during that period.